Farnesoid X receptor agonists in biliary tract disease

Current Opinion in Gastroenterology

Volumn 25, Issue 3, 2009, Pages 252-259

  Fiorucci, Stefano ^a   Baldelli, Franco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Bile acids; Cholestasis; Farnesoid X receptor; Nuclear receptors; Primary biliary cirrhosis

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 6ALPHA ETHYLCHENODEOXYCHOLIC ACID; ANDROSTANE DERIVATIVE; BILE ACID; CHENODEOXYCHOLIC ACID; FARNESOID X RECEPTOR; FEXARAMINE; HORMONE RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; MULTIDRUG RESISTANCE PROTEIN 4; PREGNANE X RECEPTOR; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; XENOBIOTIC AGENT;

BILE DUCT; BILIARY CIRRHOSIS; BILIARY TRACT DISEASE; CHOLESTASIS; HUMAN; KIDNEY CELL; LIVER CELL; LIVER INJURY; LIVER METABOLISM; NONHUMAN; REVIEW;

ANIMALS; BILIARY TRACT DISEASES; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; XENOBIOTICS;

EID: 67651123303     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328324f87e     Document Type: Review

References (53)

1. Jansen PL, Müller M, Sturm E, et al. Genes and cholestasis. Hepatology 2001; 34:1067-1074.
2. Elferink RO, Groen AK. Genetic defects in hepatobiliary transport. Biochim Biophys Acta 2002; 1586:129-145.
3. Geier A. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007; 1773:283-308. An exhaustive review of the role of nuclear receptors in regulating liver and biliary tract physiology and disorder.
4. Lee JM, Trauner M, Soroka CJ, et al. The molecular expression of the bile salt export pump, sister of P-glycoprotein, is selectively preserved in cholestatic liver injury. Gastroenterology 2000; 118:163-172.
5. Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 2001; 33:783-791. (Pubitemid 32246625)
6. Pei QL, Kobayashi Y, Tanaka Y, et al. Increased expression of multidrug resistance-associated protein 1 (mrp1) in hepatocyte basolateral membrane and renal tubular epithelia after bile duct ligation in rats. Hepatol Res 2002; 22:58-64. (Pubitemid 34223635)
7. Wagner M, Fickert P, Zollner G, et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003; 125:825-838. (Pubitemid 37070700)
8. Zollner G, Wagner M, Fickert P, et al. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 2007; 27:920-929. A study showing the cholestasis induces the basolateral transporter MRP4. (Pubitemid 47261945)
9. Boyer JL, Trauner M, Mennone A, et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006; 290:G1124-G1130. (Pubitemid 43788293)
10. Zollner G, Wagner M, Moustafa T, et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol 2006; 290:G923-G932.
11. Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am J Physiol Gastrointest Liver Physiol 2006; 290:G476-G485.
12. Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 2007; 24:1803-1823. (Pubitemid 47389235)
13. Xia X, Francis H, Glaser S, et al. Bile acid interactions with cholangiocytes. World J Gastroenterol 2006; 12:3553-3563.
14. Honda M, Kawai H, Shirota Y, et al. Differential gene expression profiles in stage I primary biliary cirrhosis. Am J Gastroenterol 2005; 100:2019-2030. (Pubitemid 43919395)
15. Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001; 33:633-646. (Pubitemid 32185226)
16. Zollner G, Fickert P, Silbert D, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003; 38:717-727. (Pubitemid 36613336)
17. Andreas G, Martin W, Christoph GD, Michael T. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta Mol Cell Res 2007; 1773:283-308.
18. Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995; 8:687-693.
19. Huber RM, Murphy K, Miao B, et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 2002; 290:35-43. (Pubitemid 34615907)
20. Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003; 278:104-110. (Pubitemid 36043550)
21. Otte K, Kranz H, Kober I, et al. Identification of farnesoid X receptor as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol 2003; 23: 864-872. (Pubitemid 36133505)
22. Pellicciari R, Costantino G, Fiorucci S. Farnesoid X Receptor: from structure to potential clinical applications. J Med Chem 2005; 48:5383-5403.
23. Fiorucci S, Rizzo G, Donini A, et al. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007; 13:298-309. A review of current status of potential therapeutic applications of FXR agonsists.
24. Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3:543-553. (Pubitemid 29268438)
25. Lee FY, Lee H, Hubbert ML, et al. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006; 31:572-580.
26. Cariou B, Staels B. FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci 2007; 28:236-243. A review of current status of potential therapeutic applications of FXR agonists in metabolic disorders.
27. Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 2006; 3:231-251. (Pubitemid 44021431)
28. Ananthanarayanan M, Balasubramanian N, Makishima M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001; 276:28857-28865. (Pubitemid 37451965)
29. Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002; 277:2908-2915. (Pubitemid 34953324)
30. Barbier O, Torra IP, Sirvent A, et al. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 2003; 124:1926-1940. (Pubitemid 36666787)
31. Gnerre C, Blättler S, Kaufmann MR, et al. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 2004; 14:635-645. (Pubitemid 39411263)
32. Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 2006; 103:3920-3925. (Pubitemid 43376656)
33. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2:217-225.
34. Jung D, Mangelsdorf DJ, Meyer UA. Pregnane x receptor is a target of farnesoid x receptor. J Biol Chem 2006; 281:19081-19091.
35. Sonoda J, Xie W, Rosenfeld JM, et al. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci U S A 2002; 99:13801-13806. (Pubitemid 35215461)
36. Zhang J, Huang W, Qatanani M, et al. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J Biol Chem 2004; 279:49517-49522. (Pubitemid 39625839)
37. Teng S, Piquette-Miller M. Regulation of transporters by nuclear hormone receptors: implications during inflammation. Mol Pharm 2008; 5:67-76. A review describing the regulation of liver transporters in inflammation. (Pubitemid 351300036)
38. Marzolini C, Tirona RG, Gervasini G, et al. A common polymorphism in the bile acid receptor farnesoid x receptor is associated with decreased hepatic target gene expression. Mol Endocrinol 2007; 21:1769-1780. (Pubitemid 47173790)
39. Van Mil SA, Milona P, Dixon R, et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007; 133:507-516.
40. Kovacs P, Kress R, Rocha J, et al. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol 2008; 48:116-124. A study suggesting a potential role of FXR gene variations in predisposing to gallstone in mice and humans.
41. Boyer JL. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J Hepatol 2007; 46:365-371.
42. Chen HL, Liu YJ, Chen HL, et al. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr Res 2008; 63:667-673.
43. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36:525-531. (Pubitemid 34977162)
44. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129:476-485. (Pubitemid 41096635)
45. Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 2003; 112:1678-1687. (Pubitemid 38063725)
46. Fiorucci S, Clerici C, Antonelli E, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 2005; 313:604-612. (Pubitemid 40604160)
47. Stedman C, Liddle C, Coulter S, et al. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci U S A 2006; 103:11323-11328. (Pubitemid 44156516)
48. Marschall HU, Wagner M, Bodin K, et al. Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J Lipid Res 2006; 47:582-592. (Pubitemid 43345599)
49. Denk GU, Soroka CJ, Takeyama Y, et al. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 2004; 40:585-591. (Pubitemid 38367779)
50. Mennone A, Soroka CJ, Cai SY, et al. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 2006; 43:1013-1021. (Pubitemid 43724626)
51. Cherrington NJ, Hartley DP, Li N, et al. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 2002; 300:97-104.
52. Assem M, Schuetz EG, Leggas M, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004; 279:22250-22257. (Pubitemid 38679421)
53. Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 2004; 10:1352-1358. (Pubitemid 40022717)